Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”), today announced the closing of its acquisition with Tenet Medicines (“Tenet”). The transaction closed on June 27, 2024. Following the closing, Eliem will focus on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy. Concurrent with the closing of the acquisition, Eliem completed a $120 million private placement of its common stock with a syndicate of new and existing institutional life science investors.
Read the full article: Eliem Therapeutics Announces the Closing of Its Acquisition of Tenet Medicines and Concurrent $120M Private Placement //
Source: https://www.globenewswire.com/news-release/2024/06/27/2905516/0/en/Eliem-Therapeutics-Announces-the-Closing-of-its-Acquisition-of-Tenet-Medicines-and-Concurrent-120-Million-Private-Placement.html